JP2023537410A5 - - Google Patents

Info

Publication number
JP2023537410A5
JP2023537410A5 JP2023509739A JP2023509739A JP2023537410A5 JP 2023537410 A5 JP2023537410 A5 JP 2023537410A5 JP 2023509739 A JP2023509739 A JP 2023509739A JP 2023509739 A JP2023509739 A JP 2023509739A JP 2023537410 A5 JP2023537410 A5 JP 2023537410A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
hydrogen
heterocycloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023509739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537410A (ja
JP7802765B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045474 external-priority patent/WO2022035923A1/en
Publication of JP2023537410A publication Critical patent/JP2023537410A/ja
Publication of JP2023537410A5 publication Critical patent/JP2023537410A5/ja
Application granted granted Critical
Publication of JP7802765B2 publication Critical patent/JP7802765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023509739A 2020-08-12 2021-08-11 オキソピロリジン尿素fpr2アゴニスト Active JP7802765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064640P 2020-08-12 2020-08-12
US63/064,640 2020-08-12
PCT/US2021/045474 WO2022035923A1 (en) 2020-08-12 2021-08-11 Oxopyrrolidine urea fpr2 agonists

Publications (3)

Publication Number Publication Date
JP2023537410A JP2023537410A (ja) 2023-08-31
JP2023537410A5 true JP2023537410A5 (cg-RX-API-DMAC7.html) 2024-08-19
JP7802765B2 JP7802765B2 (ja) 2026-01-20

Family

ID=77595649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509739A Active JP7802765B2 (ja) 2020-08-12 2021-08-11 オキソピロリジン尿素fpr2アゴニスト

Country Status (6)

Country Link
US (1) US12565483B2 (cg-RX-API-DMAC7.html)
EP (1) EP4196471A1 (cg-RX-API-DMAC7.html)
JP (1) JP7802765B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230051525A (cg-RX-API-DMAC7.html)
CN (1) CN116057055B (cg-RX-API-DMAC7.html)
WO (1) WO2022035923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
KR20250172673A (ko) * 2023-04-18 2025-12-09 브리스톨-마이어스 스큅 컴퍼니 카르보시클릭 페닐피롤리디논 우레아 fpr2 효능제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305763B1 (en) 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
AU2016266190A1 (en) 2015-05-27 2018-01-18 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
KR20180081528A (ko) 2015-11-24 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅
US10717708B2 (en) 2015-12-10 2020-07-21 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
JP2020015664A (ja) 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
WO2018217684A1 (en) 2017-05-22 2018-11-29 Bristol-Myers Squibb Company Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
KR102615095B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
JP7094989B2 (ja) 2017-06-09 2022-07-04 ブリストル-マイヤーズ スクイブ カンパニー シクロプロピルウレアホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト
EP3634956B1 (en) 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2019173182A1 (en) * 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
JP7494224B2 (ja) 2019-06-18 2024-06-03 ブリストル-マイヤーズ スクイブ カンパニー ビアリールジアルキルホスフィンオキシドfpr2アゴニスト
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
WO2022076764A1 (en) 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Aminoimidazole fpr2 agonists

Similar Documents

Publication Publication Date Title
JP2024050527A5 (cg-RX-API-DMAC7.html)
RU2007124681A (ru) Производные тетрагидропирана в качестве противодиабетических средств
US5681824A (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
FI89356B (fi) Foerfarande foer framstaellnig av blodsockerhalten saenkande samt atherosklerosis hindrande tiazolidindioner
JPH0550516B2 (cg-RX-API-DMAC7.html)
JP2024540164A5 (cg-RX-API-DMAC7.html)
JP2019531320A5 (cg-RX-API-DMAC7.html)
US20090131677A1 (en) Substituted beta-phenyl-alpha-hydroxy-propanoic acid, synthesis method and use thereof
JP2024540163A5 (cg-RX-API-DMAC7.html)
JP2021528451A5 (cg-RX-API-DMAC7.html)
JP3179599B2 (ja) 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
DE69434720T2 (de) Verwendung von 2,6-Dialkyl-4-Silyl-Phenol Derivaten zur Behandlung von Xanthom
JP2024543013A5 (cg-RX-API-DMAC7.html)
JP2023533037A5 (cg-RX-API-DMAC7.html)
JP2022537350A5 (cg-RX-API-DMAC7.html)
JP2691679B2 (ja) オキシム誘導体およびそれを含有する医薬品
JPS60208975A (ja) 血小板活性化因子拮抗剤である新規2,5−ジアリ−ルテトラヒドロチオフエン類及びその類縁体
JP2021520394A5 (cg-RX-API-DMAC7.html)
JPH01501551A (ja) 新規な医薬用途
PT650485E (pt) 2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias
JP4443036B2 (ja) ピラジン誘導体、それらの製造及びそれらを含有する薬剤
US6835846B2 (en) Aliphatic compounds, process for their preparation and their usage
JP2024540161A5 (cg-RX-API-DMAC7.html)
WO1994004546A1 (fr) Derive de moranoline
JP2024546946A5 (cg-RX-API-DMAC7.html)